PM
BCRX icon

Parametrica Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Parametrica Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,005
Closed -$260K – 183
2022
Q1 		$260K Buy
+16,005
New +$257K 0.19% 146
2014
Q4 		– Sell
-10,003
Closed -$98K – 45
2014
Q3 		$98K Buy
+10,003
New +$123K 0.57% 56

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parametrica Management's BCRX Position: Q2 2022 in Review

Parametrica Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 16,005 shares — an estimated $260K sold.

Parametrica Management first reported a position in BCRX in Q3 2014 and held it in 2 quarters. The position peaked at $260K in Q1 2022. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

  • Parametrica Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Parametrica Management sold 16,005 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $260K.
  • Parametrica Management first reported a position in BioCryst Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Parametrica Management's BioCryst Pharmaceuticals position peaked at $260K in Q1 2022.
  • 221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Parametrica Management's 13F filing for Q2 2022, filed 22 Jul 2022.